Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described. This subgroup represented 3% of all relapsed patients seen at this institution over the same time period. There were eight males in this cohort and the median age at diagnosis was 48 years (range 13 - 77 years). Nine patients had M4/M5 French - American - British (FAB) classification subtype and most had intermediate risk cytogenetics. The median duration of first complete remission (CR-1) was 9 years (range 5.2 - 11.5 years). Thirteen patients (86%) achieved CR-2 with reinduction therapy. The 5-year relapse-free survival and overall survival rates of this cohort were 59% and 51%, respectively. We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.
Medeiros
Bruno C
BC
Department of Medical Oncology, Peincess Margaret Hospital, University Health Network, Univeristy of Toronto, Toronto, Ontario, Canada.
Minden
Mark D
MD
Schuh
Andre C
AC
Schimmer
Aaron D
AD
Yee
Karen
K
Lipton
Jeff H
JH
Messner
Hans A
HA
Gupta
Vikas
V
Chun
Kathy
K
Xu
Wei
W
Das
Prabodh
P
Kamel-Reid
Suzanne
S
Brandwein
Joseph M
JM
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis